08:47:40 EDT Sun 26 Sep 2021
Enter Symbol
or Name

Login ID:
Hemostemix Inc (2)
Symbol HEM
Shares Issued 55,535,638
Close 2021-01-22 C$ 0.60
Recent Sedar Documents

Hemostemix signs BREAD deal with DFATD

2021-01-22 09:35 ET - News Release

Mr. Thomas Smeenk reports


Hemostemix Inc. has signed the Building Relationships Entrepreneurs and Dealmakers (BREAD) contract with the Department of Foreign Affairs, Trade and Development. An initiative to assist high-potential, biotech-focused Canadian small and medium enterprise (SME), the program is designed to accelerate the growth of Hemostemix and other Canadian biotechnology companies.

"We are actively working with the Trade Commissioner Service of Canada in the USA, Japan and South Korea to source qualified partners to go to market with," stated Thomas Smeenk, chief executive officer. "The BREAD agreement marks our company's starting point to outlicense ACP-01 and it generates our sponsorship into BioCom."

About the Trade Commissioner Service of Canada

The Trade Commissioner Service (TCS) plays an active role in helping Canadian companies achieve their goals of growth into international markets. Its services focus on helping companies prepare for international markets, assessing market potential, finding qualified contacts and partners, and resolving problems.

About Hemostemix Inc.

Hemostemix is an autologous stem-cell therapy company founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company developed and is commercializing its lead product, ACP-01, for the treatment of critical limb ischemia, peripheral artery disease, angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On Oct. 21, 2019, the company announced the results from its phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up," which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years.

The company owns 91 patents across five patent families titled: regulating stem cells, in vitro techniques for use with stem cells, production from blood of cells of neural lineage and automated cell therapy.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.